Genvor (GNVR)

Woodland, California-based Genvor Inc. (OTCQB: $GNVR) announced a formal teaming agreement with Tuskegee University to advance next-generation AI-accelerated peptide technology for sustainable agriculture through joint research, testing, and grant-supported development. Genvor Inc. is a B2i Digital Featured Company. A full profile will be available soon at https://b2idigital.com/featured-companies. The Tuskegee partnership strengthens Genvor’s research capabilities by providing access to university laboratories, scientific instrumentation, and the next generation of agricultural scientists, enabling faster innovation cycles and expanded validation of its proprietary peptide-based crop protection technologies. Among the highlights from the announcement: • Joint research through Tuskegee’s Center for Biomedical Research focusing on biological manufacturing and novel peptide sequences for crop protection, resilience, and nutrient performance • Access to world-class research facilities and next-generation agricultural scientists to accelerate product development and field validation • Collaborative framework for grant-supported development bridging university research with commercial applications • Strategic alignment with Tuskegee’s reputation for solving complex agricultural challenges and training students in sustainable farming innovation Discussing the collaboration with Tuskegee University, Genvor CEO Chad Pawlak noted, “This partnership marks a pivotal step in Genvor’s mission to enhance biological crop protection through the power of peptides. Tuskegee University’s scientific excellence and access to world-class research facilities create the perfect environment to accelerate innovation and bring forward solutions that meet the demands of today’s agricultural challenges.” See the news release at: https://genvor.com/press-releases/post?storyId=6992306354436899 Genvor is led by CEO Chad Pawlak, with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit https://www.genvor.com. For investor inquiries, contact [email protected] Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

$GNVR 🤝

The B2i Digital team is pleased to introduce Genvor Inc. (OTCQB: $GNVR) as a new B2i Digital Featured Company. A complete company profile will be available soon at https://b2idigital.com/featured-companies. Genvor is a Woodland, California-based agricultural biotechnology company that uses AI-accelerated peptide design to develop sustainable crop protection solutions. Founded in 2018, Genvor specializes in creating antimicrobial, insecticidal, and nutrient-enhancing peptides using its proprietary BioCypher Algorithm to address the estimated $220 billion annual global crop loss crisis. The company’s peptide technologies are designed for both foliar spray applications and seed trait integration across row and specialty crops. In November 2025, Genvor announced the issuance of U.S. Patent No. 12,458,684 for transgenic corn with antifungal peptide AGM182, demonstrating 76-98% reduction in aflatoxin contamination. This patent, co-assigned with the USDA, adds to Genvor’s intellectual property portfolio of 5 issued U.S. patents, 2 pending U.S. patent applications, and 4 additional applications in preparation. The company’s lead antimicrobial peptides have shown broad-spectrum efficacy against major agricultural pathogens, including Aspergillus flavus and Fusarium species, at low concentrations. With over 50,000 designed peptides in its digital library and 30+ years of foundational research, Genvor’s platform enables rapid development of biological alternatives to traditional fungicides. The company is actively engaged with major agricultural companies for joint ventures and commercialization. Through its 7+ year USDA Collaborative Research Agreement (CRADA), Genvor is developing corn varieties that are resistant to pre-harvest aflatoxin contamination and have enhanced nutritional profiles for animal feed. Genvor is led by CEO Chad Pawlak, with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. To learn more about Genvor Inc., visit https://genvor.com/. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

$GNVR #OTCMarkets #OTCStocks #AgTech #peptides #biotech OTC Markets Group Welcomes New OTCQB Companies - https://www.otcmarkets.com/stock/GNVR/news/OTC-Markets-Group-Welcomes-New-OTCQB-Companies---November-17?id=500166

$GNVR announces USPTO patent for AGM182 antifungal corn tech! Co-assigned w/USDA. 76-98% reduction in aflatoxin contamination. Addresses $52M-$1.68B annual aflatoxin losses + broader $3.X-5B fungal disease impact. Expanding IP portfolio! 🌽 #AgTech #Biotech #OTCMarkets https://www.otcmarkets.com/stock/GNVR/news/Genvor-Announces-Issuance-of-New-US-Patent-for-Corn-with-Antifungal-Peptide?id=499680

$GNVR #Peptides #biotech #OTCQB #OTCMARKETS #USSTOCKS #CropProtection

$GNVR #CropProtection #Biologicals #biotech #Peptides Genvor | Bayer’s Award https://share.google/NJ7b30FMUKZ03LVXy

$MLGO JANOVER $GNVR kept the fire today. But have we seen the best of $MLGO yet?. $HOLO ........i won't back down. What do i have to loose?

$GNVR Anyone have DD they can share on this company outlook, price predictions?